Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minocycline augmentation for SSRI/SNRI-resistant major depressive disorder with childhood trauma
ChiCTR2400086345Phase 4Not yet recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of minocycline in major depressive disorder (MDD) (2 arms), sponsored by The Second Xiangya Hospital. Primary endpoints: Montgomery-Asberg Depression Rating Scale at week 8, Hamilton Depression Scale at week 8 and 1 more. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
minocycline
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2400086345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086345.